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Purpose: The incidence of papillary thyroid carcinomas (PTCs) is rapidly increasing in Korea. Analyzing the gene expression 
profiling (GEP) of PTCs will facilitate the advent of new methods in diagnosis, prognostication, and treatment. We per-
formed this study to find the GEP of Korean PTCs. Methods: We performed oligonucleotide microarray analysis with 19 
PTCs and 7 normal thyroid glands. Differentially expressed genes were selected using a t-test (|fold| ＞3) and adjusted 
Benjamini-Hochberg false discovery rate P-value ＜ 0.01. Quantitative reverse transcription-polymerase chain reaction 
(QRT-PCR) was used to validate microarray data. A classification model was developed by support vector machine (SVM) al-
gorithm to diagnose PTCs based on molecular signatures. Results: We identified 79 differentially expressed genes (70 
up-regulated and 9 down-regulated) according to the criteria. QRT-PCR for five genes (CDH3, NGEF, PROS1, TGFA, MET) 
was confirmatory of the microarray data. Hierarchical cluster analysis and a classification model by the SVM algorithm accu-
rately differentiated PTCs from normal thyroid gland based on GEP. Conclusion: A disease classification model showed ex-
cellent accuracy in diagnosing PTCs, thus showing the possibility of molecular diagnosis in the future. This GEP could serve 
as baseline data for further investigation in the management of PTCs based on molecular signatures.
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INTRODUCTION
The incidence of thyroid carcinoma is rapidly increas-
ing in Korea and in several regions of the world [1-3]; most 
of the increase is due to the early detection of small papil-
lary thyroid carcinoma (PTC). In Korea, PTCs comprise 
approximately 95% of thyroid carcinomas and 90% are 
PTCs of the classic type [4]. 
Although fine needle aspiration biopsy (FNAB) is the 
choice of diagnostic tests for most thyroid nodules, an in-
determinate (10 to 20%) and inadequate (10 to 15%) diag-
nosis imposes a dilemma for clinicians and undermines 
the diagnostic value of FNABs. In this context, several mo-
lecular diagnostic techniques focusing on the detection of 
genetic alterations have been designed, but this approach 
also has limitations because genetic alterations are not Ki-Wook Chung, et al.
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found in all thyroid carcinomas. Thus, there is a hope that 
detection of differential gene expression profiling (GEP) of 
thyroid carcinomas can be used as a diagnostic marker 
and improve the diagnostic value of FNABs of thyroid 
nodules.
Paik et al. [5] proposed that GEP of 21 genes selected 
from previous published microarray analyses can accu-
rately predict the prognosis of patients with breast cancer. 
It is also possible that the accumulation of microarray and 
clinic-pathologic data will facilitate the use of GEP in esti-
mating the prognosis of thyroid carcinomas.
Furthermore, analyzing the pattern of GEP in PTCs will 
shed light for identifying a molecular target of treatment 
and the adoption of personalized molecular medicine in 
treatment.
In this study we determined the global GEP of PTCs in 
Korean patients compared to normal thyroid gland tissues 
using oligonucleotide microarray, which contains 24,000 
transcripts. We also tested five up-regulated genes to vali-
date the microarray technique. 
METHODS
Tissue samples 
The samples for this study were randomly selected and 
obtained from 19 PTCs and 7 controls of normal thyroid 
tissue from contra-lateral lobes (all paired with PTCs) at 
the time of surgery from patients who underwent total 
thyroidectomies at the National Cancer Center between 
December 2006 and December 2007. All contra-lateral 
lobes were normal on preoperative ultrasound imaging. 
Gross specimens were carefully examined to reduce the 
chance of including occult carcinoma in control samples. 
The tissues were immediately snap-frozen and stored at 
-80
oC until use. The purity of the samples was confirmed 
by microscopic examination under frozen section before 
RNA extraction. All carcinoma samples contained pure 
carcinomas and normal thyroid tissue. The medical re-
cords were reviewed to define the clinical features of each 
case. Informed consent was obtained from all patients. 
This study was approved by the Institutional Review 
Board of the National Cancer Center.
RNA preparation
Total RNA was extracted using Trizol (Invitrogen, 
Carlsbad, CA, USA) and purified using RNeasy columns 
(Qiagen, Hilden, Germany) according to the manu-
facturers’ protocols. After processing with DNase diges-
tion and clean-up procedures, RNA samples were quanti-
fied, aliquotted, and stored at -80°C until use. For quality 
control, RNA purity and integrity were evaluated by de-
naturing gel electrophoresis (OD 260/280 ratio) and ana-
lyzed on an Agilent 2100 Bioanalyzer (Agilent Technolo-
gies, Santa Clara, CA, USA). 
Oligonucleotide microarray analysis 
Total RNA was amplified and purified using the 
Ambion Illumina RNA amplification kit (Ambion, Austin, 
TX, USA) to yield biotinylated cRNA according to the 
manufacturer’s instructions. Briefly, 550 ng of total RNA 
was reverse-transcribed to cDNA using a T7 oligo(dT) 
primer. Second-strand cDNA was synthesized, in vitro- 
transcribed, and labeled with biotin-NTP. After purifica-
tion, the cDNA was quantified using a ND-1000 Spec-
trophotometer (NanoDrop, Wilmington, DE, USA). Label-
ed cDNA (750 ng) samples were hybridized to each 
Illumina Human-8 Expression Bead Chip (Illumina Inc., 
San Diego, CA, USA) for 16 to 18 hours at 58
oC according 
to the manufacturer's instructions. The Human-8 Express-
ion Bead Chip microarray contains 23920 probes derived 
from the National Center for Biotechnology Information 
Reference Sequence (NCBI RefSeq) database (Build 36.2, 
Release 22). Detection of the array signal was carried out 
using Amersham fluorolink streptavidin-Cy3 (GE 
Healthcare Bio-Sciences, Piscataway, NJ, USA) following 
the bead array manual. Arrays were scanned with an 
Illumina BeadArray Reader (Illumina Inc.) confocal scan-
ner according to the manufacturer's instructions. 
Data analysis
Array data export processing and analysis was perfor-
med using Illumina BeadStudio ver. 2.1.12 (Illumina Inc.). 
The quality of hybridization and overall chip performance 
were monitored by visual inspection of both internal qual-
ity control checks and the raw scanned data. Raw data 
were extracted and filtered by a detection P-value ＜  0.05 Gene expression profiling of papillary thyroid carcinoma
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Characteristic Value
Age (yr) 48.3 ± 3.08
Female gender 15 (78.9)
Peri-thyroidal soft tissue extension 15 (78.9)
Gross extension   3 (15.8)
Multi-focality   8 (42.1)
Angiolymphatic invasion   6 (31.6)
Lymph node metastasis
 Central   9 (47.4)
 Lateral   4 (21.1)
Stage
a)
 I 10 (52.6)
 II   0 (0)
 III   6 (31.6)
 IV   3 (15.8)
Values are presented as mean ± SD or number (%).
a)American Joint Committee on Cancer, 6th ed., stage of disease.
Table 1. Clinical characteristics of patients with papillary thyroid 
carcinomas (n = 19)
(similar to signal-to-noise) in at least 50% of the samples; a 
filtering criterion for data analysis was applied and a high-
er signal value was required to obtain a detection P-value 
＜  0.05. The selected gene signal value was transformed by 
logarithm and normalized by the quantile method. The 
comparative analysis between PTCs and controls (normal 
thyroid gland) was carried out using a t-test (|fold|＞3) 
and an adjusted Benjamini-Hochberg false discovery rate 
(FDR) P-value ＜  0.01 [6]. 
Hierarchical cluster analysis was performed using com-
plete linkage and Euclidean distance as a measure of 
similarity. Classifications were made using a support vec-
tor machine (SVM) algorithm in ArrayAssist (Stratagene, 
La Jolla, CA, USA); 16 samples (10 PTCs and 6 controls) 
were used by training, and 10 samples (9 PTCs and 1 con-
trol) were validated. All data analysis and visualization of 
differentially expressed genes was conducted using 
ArrayAssist. Biological pathway and gene function-based 
analysis were performed by using the protein analysis 
through evolutionary relationships (PANTHER) database 
(http://www.pantherdb.org). The PANTHER classifica-
tion system is a resource that classifies genes by function 
using published scientific experimental evidence and evo-
lutionary relationships to predict function even in the ab-
sence of direct experimental evidence.
Quantitative reverse transcription-polymerase chain 
reaction (QRT-PCR)
A TaqMan real-time RT-PCR kit (Applied Biosystems, 
Foster City, CA, USA) was used to detect and quantify spe-
cific mRNA expression in PTCs and controls. Briefly, a 
2-μg aliquot of RNA was converted to cDNA using a high 
capacity cDNA reverse transcription kit (Applied Biosys-
tems). The cDNA products are diluted and an aliquot of 
cDNA equivalent to 10 ng of total RNA was used for quan-
titative real-time PCR performed using primers and 
TaqMan probes supplied from Applied Biosystems. The 
assays include cadherin 3, type 1, P-cadherin (CDH3, 
NM_001793.3), neuronal guanine nucleotide exchange 
factor (NGEF, NM_019850.1), met proto-oncogene (MET, 
NM_000245.2), protein S (PROS1, NM_000313.1), and 
transforming growth factor alpha (TGFA, NM_ 003236.1).
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
was used as an endogenous control for normalizing the 
RNA concentration. Real-time PCR was performed with 
the ABI 7700 sequence detection system. 
Standard thermal cycling cycle threshold (CT) values for 
each gene were obtained for each sample. Differences in 
the CT values between a test gene and endogenous con-




Nineteen classic PTC samples were collected and the 
normal thyroid glands of the contra-lateral lobe were 
gathered from seven out of nineteen patients for controls. 
The mean age of the patients was 48.3 years (range, 29 to 78 
years) and 78.9% of the patients (15/19) were females. The 
clinical characteristics of the patients with PTCs are pre-
sented in Table 1.
Differentially-expressed genes in PTCs and normal 
thyroid glands
To identify the genes that were differentially-expressed 
between PTCs and normal thyroid gland tissues, we ap-
plied a strict threshold in comparative analysis (a t-test Ki-Wook Chung, et al.
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Gene symbol Accession no.
a)  Fold-change (T/N) Gene symbol Accession no. Fold-change (T/N)
CDH3 NM_001793.3 10.61 BHLHB3 NM_030762.1 3.62
PROS1 NM_000313.1 8.67 PERP NM_022121.2 3.60
NGEF NM_019850.1 8.08 EVA1 NM_005797.2 3.58
METTL7B NM_152637.1 7.72 DUSP4 NM_057158.2 3.58
FLJ41841 NM_207499.1 7.33 IL1RAP NM_002182.2 3.50
PDE5A NM_033437.2 6.45 XPR1 NM_004736.2 3.47
NRCAM NM_005010.2 6.32 PRSS23 NM_007173.3 3.47
TUSC3 NM_006765.2 6.18 TBC1D2 NM_018421.2 3.46
PSD3 NM_206909.1 6.02 HPN NM_002151.1 3.43
GALE NM_000403.3 6.01 ELF3 NM_004433.3 3.36
LONRF2 NM_198461.1 5.66 ARNTL NM_001178.4 3.33
SCEL NM_003843.2 5.19 C6orf168 NM_032511.1 3.32
CTXN1 NM_206833.1 5.00 ULBP2 NM_025217.2 3.32
GJB3 NM_001005752.1 4.97 ADRA1B NM_000679.3 3.31
KIAA1202 NM_020717.1 4.81 RXRG NM_006917.3 3.29
MFGE8 NM_005928.1 4.78 DOCK9 NM_015296.1 3.27
MXRA8 NM_032348.2 4.77 IER5L NM_203434.1 3.25
MTMR11 NM_181873.1 4.44 B3GNT3 NM_014256.2 3.25
CXorf6 NM_005491.1 4.36 CSF2 NM_000758.2 3.22
P4HA2 NM_001017974.1 4.36 HEY2 NM_012259.1 3.21
LAD1 NM_005558.3 4.24 SIPA1L2 NM_020808.1 3.21
ABCC3 NM_020037.1 4.19 ECE1 NM_001397.1 3.21
MET NM_000245.2 4.11 ADAMTS9 NM_182920.1 3.20
KLK10 NM_145888.1 4.09 IGF2BP2 NM_006548.4 3.19
CLDN9 NM_020982.2 4.09 WIG1 NM_152240.1 3.14
EVA1 NM_144765.1 4.09 PPL NM_002705.3 3.14
PTPRE NM_006504.3 3.97 LIFR NM_002310.3 -3.12
SDC4 NM_002999.2 3.90 FLJ37266 NM_175892.3 -3.16
STK32A NM_145001.1 3.83 MAFB NM_005461.3 -3.33
TPD52L1 NM_001003396.1 3.80 BMP2 NM_001200.1 -3.38
ERBB3 NM_001982.2 3.79 ARHGAP24 NM_001025616.1 -3.46
PDLIM4 NM_003687.2 3.79 TBC1D4 NM_014832.1 -3.58
PLAG1 NM_002655.1 3.76 PIP3-E NM_015553.1 -4.05
UPP1 NM_181597.1 3.72 ANKRD37 NM_181726.1 -4.29
EVA1 NM_144765.1 3.67 　　
T, tumor; N, normal thyroid tissue.
a)Genbank gene identification number. 
Table 2. List of differently-expressed genes in microarray analysis: negative fold-changes represent down-regulation of the gene 
|fold|  ＞3 and an adjusted Benjamini-Hochberg FDR 
P-value ＜ 0.01). In the comparison analysis between 19 
PTCs and 7 controls, 70 genes were identified as up-regu-
lated and 9 genes as down-regulated in PTCs according to 
the criteria (Table 2). 
When we classified 79 differentially-expressed genes 
according to their biological process and molecular func-
tion using the PANTHER database, the highest involved 
biologic process was signal transduction (38%, 30/79) fol-
lowed by the developmental process (19%, 15/79), protein 
metabolism/modification (16%, 13/79). According to mo-
lecular funtion classification, the receptor (14%, 11/79) is 
the leading functional class of differentially-expressed 
genes, followed by transcription factor (10%, 8/79), cell ad-
hesion molecule (10%, 8/79), Detailed distributions of the 
differentially-expressed genes are displayed in Fig. 1A, B.
Hierarchical cluster analysis showed that PTCs were 
well-discriminated from controls, with the exception of 
one case which showed overlap between PTCs and con-
trols, indicating the possibility of selecting a group of 
genes for the diagnosis of PTCs. Detailed results of hier-
archical cluster analysis is shown in Fig. 2. Data from one Gene expression profiling of papillary thyroid carcinoma
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Fig. 1. Molecular characteristics of differentially expressed genes between papillary thyroid carcinomas and normal thyroid glands. (A) 
Molecular characteristics according to biological process (B) molecular characteristics according to molecular function.
Fig. 2. Hierarchical cluster 
analysis of genes associated 
with papillary thyroid carci-
nomas (PTCs). Columns re-
present 19 PTCs and 7 
normal thyroid glands (con-
trols). Rows show the 79 
differentially expressed ge-
nes between PTCs and 
controls. The heatmap indi-
cates up-regulation (red), 
down-regulation (green) and 
average (black) gene expres-
sion.Ki-Wook Chung, et al.
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Fig. 3. Validation of microarray analysis by quantitative reverse 
transcription-polymerase chain reaction (QRT-PCR). Expression 
status was well-matched with QRT-PCR results, with the exception 
of non-equilibrium Green's function (NEGF). However, NEGF 
expression was up-regulated in oligonucleotide microarray ana-
lysis and QRT-PCR results. CDH3, cadherin 3, type 1, P-cadherin; 
NGEF, neuronal guanine nucleotide exchange factor; MET, met 
proto-oncogene; PROS1, protein S; TGFA, transforming growth 
factor alpha.




a) PTC PTC 0.73727816
MX7 PTC PTC 0.7595941
MX8 PTC PTC 0.94525576
MX9 PTC PTC 0.79724693
MX10 PTC PTC 0.761422
MO3
b) PTC PTC 0.7481214
MO6 PTC PTC 0.81863475
MO7 PTC PTC 0.5090502
MO9 PTC PTC 1
N2
c) Normal Normal 0.94844013
Probability of error was expected less than 0.01 when confidence 
measure was more than 0.5.
PTC, papillary thyroid carcinoma; Identifier, tissue identifi-
cation number.
a)PTC with lymph node metastasis. 
b)PTC without lymph node 
metastasis. 
c)Normal thyroid tissue. 
Table 3. Confidence measure to calculate accuracy of validation 
test. Nine PTCs and one normal thyroid tissues are completely 
discriminated from each other with 90 gene probe classification 
model
PTC sample which showed no discrimination is excluded 
in this figure. 
Validation of the microarray-derived data by 
quantitative RT-PCR
To verify the reproducibility of these genes, we per-
formed QRT-PCR using the same RNA used for micro-
array analysis (Fig. 3). The following five representative 
genes were used: CDH3 (NM_001793.3), NGEF (NM_ 
019850.1), MET (NM_000245.2), PROS1 (NM_000313.1), 
and TGFA (NM_003236.1). GAPDH expression was ana-
lyzed as a control. The QRT-PCR showed consistent re-
sults with those obtained from the oligonuleotide micro-
array, except that QRT-PCR showed a 3.9-fold increased 
expression compared to oligonucleotide microarray data 
for non-equilibrium Green's function (NEGF).
Classification by the SVM algorithm 
Classification model by SVM algorithm was con-
structed to differentiate PTC from normal thyroid tissue. 
Ninety gene probes were selected from raw data with arbi-
trary criteria of a FDR adjusted P-value ＜  0.01 and an ab-
solute fold-change ＞3. A training classification model 
was formed according to the SVM algorithm from 10 PTCs 
and 6 controls. Probability of error was expected less than 
0.01 when confidence measure was more than 0.5. 
Training model discriminated PTC from normal thyroid 
tissue with 100% of accuracy. Then with this 90 probe clas-
sification model, remaining samples from 9 PTCs and 1 
control were used to validate possible prediction of PTC. 
This validation test revealed also 100% accuracy in dis-
criminating PTCs and normal thyroid gland (Table 3).
DISCUSSION
In this study, we performed GEP analysis using oligo-
nucleotide microarray and identified 79 differentially-ex-
pressed genes (70 up-regulated and 9 down-regulated) be-
tween PTCs and normal thyroid glands which could serve 
as potential diagnostic and therapeutic targets in the man-
agement of PTCs in Korean patients. This study also dem-
onstrated the possibility of using differential gene ex-
pression in the molecular diagnosis of PTCs using a classi-
fication model designed by the SVM algorithm. This GEP 
analysis was performed with Illumina’s Human-8 Ex-
pression Bead Chip, which contains 23920 probes derived 
from the NCBI RefSeq database. This oligonucleotide mi-Gene expression profiling of papillary thyroid carcinoma
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croarray has never been used for thyroid carcinomas. 
Furthermore, the criteria of selection for differentially-ex-
pressed genes were rather strict that the absolute 
fold-change ＞3 and a FDR adjusted P-value ＜  0.01 were 
adopted, whereas many other studies about microarray 
analysis of thyroid carcinomas used a 2-fold change and a 
P-value ＜  0.05 [7-9]. 
Genes associated with signal transduction were the 
most common up-regulated genes. This finding seems to 
be reasonable because the RAS-BRAF-MAPK and 
PI3K-AKt pathways are the most important molecular 
mechanisms in the carcinogenesis of PTCs [10]. However, 
cross-talking between other signal transduction pathways 
may be present because several genes associated with oth-
e r  s i g n a l  t r a n s d u c t i o n  p a t h w a y s  w e r e  f o u n d  i n  o u r  
analysis. 
A large-scale meta-analysis of cancer microarray data is 
known to differentiate important genes from false-pos-
itive genes in a large number of candidate gene lists from 
DNA microarray data [11]. In that context, Griffith et al. 
[12] conducted a comprehensive meta-analysis of thyroid 
carcinoma GEP studies in 2006 to identify meaningful 
biomarkers. Griffith et al. [12] reviewed 21 published stud-
ies, in which 34 comparisons were performed from 10 dif-
ferent expression platforms of microarrays and showed 
that 39 genes (23 up-regulated and 16 down-regulated in 
thyroid carcinoma) showed the same expression patterns 
among thyroid carcinoma, regardless of the tumor type, in 
an overlap of 3 or more studies. Among the 23 up-regu-
lated genes in thyroid carcinoma from their study, 7 genes 
(MET, TGFA, PROS1, PSD3, SDC4, TUSC3, and P4HA2) 
were also selected as members of 70 up-regulated genes in 
our study. Recently, Kim et al. [13] reported gene ex-
pression profiling of Korean PTCs. Their results showed 
different up-regulated or down-regulated genes with our 
results. Discordance between similarly designed studies 
may be caused from technical error or difficulties of re-
producibility in microarray experiment. However, the 
present study included greater number of sample size and 
decreased chance of including parenchyma cells using mi-
croscopic exam of tumor samples before RNA prepara-
tion.     
MET oncogene encodes the c-MET protein. c-Met pro-
tein is a hepatocellular growth factor receptor and is 
known to be responsible for the motility and mitogenesis 
of epithelial cells, including cancer cells [14]. Several stud-
ies reported c-MET protein expression in thyroid carcino-
ma as a useful diagnostic and prognostic marker [15]. 
Increased c-MET expression has been associated with a 
higher risk for metastasis [3] and recurrence [3,5] of PTCs. 
TGFA encodes transforming growth factor alpha protein. 
TGFA stimulates the growth and proliferation of cells and 
its over-expression has been correlated with patient sur-
vival in a variety of tumors. TGFA is closely related to epi-
dermal growth factor (EGF) and binds to the EGF re-
c e p t o r s  ( E G F R )  a s  a  l i g a n d .  T G F A  i s  r e p o r t e d  t o  b e  
up-regulated in some human carcinomas [16]. Bergstrom 
et al. [17] proposed that increased expression of TGFA 
may cause aberrant activation of EGFRs and ultimately 
led to over-expression and activation of c-MET. PROS1 co-
des for the vitamin-K-dependent plasma protein (protein 
S), which is an essential anticoagulant and multifunctional 
protein [18]. The association of protein S and thrombosis is 
well-established, but its role in cancer is not studied. The 
up-regulation of PROS1 was eminent in the meta-analysis 
of Griffith et al. [12] and our study also showed a marked 
increase of PROS1 transcripts in microarray (9-fold) and 
QRT-PCR (12-fold) among PTCs compared to normal thy-
roid gland. PSD3 is located in chromosome 8p21. A 
meta-analysis of gene expression in breast carcinomas 
showed that PSD3 is down-regulated in metastasizing tu-
mors and was identified as a candidate metastasis sup-
pressor gene [19]. However, there are no reports about its 
role in thyroid carcinomas. SDC4 is found on chromosome 
20 and encodes a transmembrane (type I) heparan sulfate 
proteoglycan that functions as a main cell adhesion re-
ceptor involved in focal adhesion formation and is re-
quired for cell migration [20]. Tumor suppressor candi-
date 3 (TUSC3) is a candidate tumor suppressor gene and 
is located on chromosome 8p22, which is a homo-
zygous-deleted region of a pancreatic cancer [21]. It is in-
teresting that TUSC3 is up-regulated in PTCs, whereas it is 
down-regulated by chromosomal deletion in pancreas 
cancer. Prolyl 4-hydroxylase, alpha polypeptide II 
(P4HA2) is located in 5q31 and encodes a component of 
prolyl 4-hydroxylase, a key enzyme in collagen synthesis Ki-Wook Chung, et al.
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composed of two identical alpha subunits and two beta 
subunits [22]. Prolyl 4-hydroxylase catalyzes the for-
mation of 4-hydroxyproline, which is essential to the 
proper three-dimensional folding of newly synthesized 
procollagen chains. Teodoro et al. [23] reported that 
p53-mediated inhibition of angiogenesis in cancer is thor-
ough via up-regulation of P4HA2. 
In addition to the 7 genes in agreement with the meta- 
analysis of Griffith et al. [12], we focused on two more 
genes which showed increased up-regulation in this mi-
croarray experiment (CDH3, 10.6-fold; NGEF, 8.1 fold). 
CDH3 is the highest up-regulated gene in this microarray 
analysis. This gene is located on chromosome 16q22 and is 
a classical cadherin from the cadherin superfamily and 
encodes P-cadherin, which is a membrane glycoprotein 
that functionally mediates tumor cell adhesion [24]. P-cad-
herin over-expression is strongly associated with tumor 
aggressiveness and a poor prognostic marker in breast 
cancer [25]. Furthermore, monoclonal antibody (PF- 
03732010) against P-cadherin has anti-tumor and an-
ti-metastatic activity in a tested xenograft model and is 
now in a Phase 1 clinical trial [26]. If PTCs overexpress 
P-cadherin, P-cadherin also could be a candidate for this 
kind of therapy in intractable cases with PTCs. NGEF is lo-
cated on 2q37 and functions as a guanine nucleotide ex-
change factor for the Rho-type GTPases. Although NGEF 
showed transforming potential in cell culture and was 
able to induce tumors in nude mice [27], further studies 
are lacking and its role in carcinogenesis needs to be clari-
fied in the future. Interestingly, NEGF expression was 
more prominent in validation experiment using quantita-
tive RT-PCR. This suggests that NEGF expression plays 
more important role in PTC because quantitative RT-PCR 
is more sensitive method to detect gene expression than 
microarray. 
The diagnosis of PTC based on FNAB has limitations 
because of “indeterminate” results, which accounts for 15 
to 20% of FNAB results [10]. Molecular diagnostic markers 
could be helpful to discriminate malignant thyroid nod-
ules from benign nodules. Our GEP analysis using a SVM 
algorithm successfully discriminated PTCs from normal 
thyroid tissues. SVM algorithm is a powerful method to 
classify differences between two groups with large num-
ber of data. Yukinawa et al. [28] reported feasibility of GEP 
based diagnosis using SVM algorithm in thyroid tumors 
even though the accuracy was 85.7%. However, future 
study should select a more concise gene cluster to analyze 
it from FNAB samples because diagnosis of thyroid nod-
ule are made by FNAB mostly [29].  
There were some limitations in this study. First, al-
though GEF is a powerful technique that is capable of pro-
viding new leads in the understanding of molecular mech-
anisms of PTCs, there still exists the possibility of 
false-positive discovery in the 79 selected genes of our 
study. Thus, the selected genes from our study need to be 
clarified about its role in carcinogenesis of PTCs through 
further studies. Second, we used mRNA from bulk tu-
mors, which could contain inflammatory cells, stroma 
cells, endothelial cells, and fibroblasts in addition to can-
cer cells. To reduce the bias from the contamination of the 
other aforementioned cells, Nikolova et al. [30] used a la-
ser microdissection technique to enrich the tumor cell 
population in their microarray study. Although we did not 
use a microdissection method for the samples in this 
study, we checked every sample before mRNA extraction 
so that every tumor specimen should contain ＞90% of tu-
mor cells. Thus, we think that this approach will reduce 
the chance of contamination from various cells other than 
PTCs.
In conclusion, we investigated GEP of PTCs compared 
with normal thyroid gland and identified 70 up-regulated 
and 9 down-regulated genes in PTCs. A disease classi-
fication model using the SVM algorithm showed excellent 
accuracy in diagnosing PTCs only by GEP.
We anticipate that the results of this study involving 
GEP will shed light on a better understanding of PTCs in 
Korea and lead to discover novel diagnostic molecular 
tests of PTCs.
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